Piper Sandler Upgrades Fate Therapeutics to Overweight, Raises Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has upgraded Fate Therapeutics (NASDAQ:FATE) from Neutral to Overweight and raised the price target from $4 to $6.
June 17, 2024 | 10:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has upgraded Fate Therapeutics from Neutral to Overweight and increased the price target from $4 to $6, indicating a positive outlook for the stock.
The upgrade from Neutral to Overweight and the increase in price target from $4 to $6 by Piper Sandler suggests a positive outlook for Fate Therapeutics. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100